Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke

S. C. Fagan, L. B. Morgenstern, A. Petitta, R. E. Ward, B. C. Tilley, J. R. Marler, S. R. Levine, J. P. Broderick, T. G. Kwiatkowski, M. Frankel, T. G. Brott, M. D. Walker

Research output: Contribution to journalArticle

320 Scopus citations

Abstract

Tissue plasminogen activator (tPA) has been shown to improve 3-month outcome in stroke patients treated within 3 hours of symptom onset. The costs associated with this new treatment will be a factor in determining the extent of its utilization. Data from the NINDS rt-PA Stroke Trial and the medical literature were used to estimate the health and economic outcomes associated with using tPA in acute stroke patients. A Markov model was developed to estimate the costs per 1,000 patients eligible for treatment with tPA compared with the costs per 1,000 untreated patients. One-way and multiway sensitivity analyses (using Monte Carlo simulation) were performed to estimate the overall uncertainty of the model results. In the NINDS rt-PA Stroke Trial, the average length of stay was significantly shorter in tPA- treated patients than in placebo-treated patients (10.9 versus 12.4 days; p = 0.02) and more tPA patients were discharged to home than to inpatient rehabilitation or a nursing home (48% versus 36%; p = 0.002). The Markov model estimated an increase in hospitalization costs of $1.7 million and a decrease in rehabilitation costs of $1.4 million and nursing home cost of $4.8 million per 1,000 eligible treated patients for a health care system that includes acute through long-term care facilities. Multiway sensitivity analysis revealed a greater than 90% probability of cost savings. The estimated impact on long-term health outcomes was 564 (3 to 850) quality- adjusted life-years saved over 30 years of the model per 1,000 patients. Treating acute ischemic stroke patients with tPA within 3 hours of symptom onset improves functional outcome at 3 months and is likely to result in a net cost savings to the health care system.

Original languageEnglish (US)
Pages (from-to)883-890
Number of pages8
JournalNeurology
Volume50
Issue number4
DOIs
StatePublished - Apr 1998

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke'. Together they form a unique fingerprint.

  • Cite this

    Fagan, S. C., Morgenstern, L. B., Petitta, A., Ward, R. E., Tilley, B. C., Marler, J. R., Levine, S. R., Broderick, J. P., Kwiatkowski, T. G., Frankel, M., Brott, T. G., & Walker, M. D. (1998). Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology, 50(4), 883-890. https://doi.org/10.1212/WNL.50.4.883